Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $9.0 million.

  • Regenxbio's Share-based Compensation fell 896.4% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.7 million, marking a year-over-year decrease of 410.37%. This contributed to the annual value of $38.5 million for FY2024, which is 448.01% down from last year.
  • According to the latest figures from Q3 2025, Regenxbio's Share-based Compensation is $9.0 million, which was down 896.4% from $8.7 million recorded in Q2 2025.
  • Regenxbio's Share-based Compensation's 5-year high stood at $11.2 million during Q1 2023, with a 5-year trough of $8.3 million in Q4 2023.
  • For the 5-year period, Regenxbio's Share-based Compensation averaged around $9.7 million, with its median value being $9.7 million (2021).
  • In the last 5 years, Regenxbio's Share-based Compensation surged by 2373.71% in 2021 and then crashed by 1431.38% in 2024.
  • Regenxbio's Share-based Compensation (Quarter) stood at $9.2 million in 2021, then grew by 2.69% to $9.4 million in 2022, then dropped by 11.37% to $8.3 million in 2023, then grew by 14.44% to $9.5 million in 2024, then dropped by 5.7% to $9.0 million in 2025.
  • Its last three reported values are $9.0 million in Q3 2025, $8.7 million for Q2 2025, and $8.5 million during Q1 2025.